Organization | Ryerson University

Ryerson University Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Toronto Canada (1948)

Organization Overview

First Clinical Trial

2008

NCT00620789

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Ryerson University

Active Ingredients

Drugs in Phase 4 Trials (2)

emtricitabine (emtriva) (1 trial)

tenofovir (viread) (1 trial)

Drugs in Phase 2 Trials (1)

Drugs in Other Trials (14)

corn syrup (1 trial)

dark chocolate (1 trial)

egg white (1 trial)

egg yolk (1 trial)

escitalopram (lexapro) (1 trial)

glucose (1 trial)

lactobacillus delbrueckii (1 trial)

lexipro (1 trial)

orange juice (1 trial)

sucralose (1 trial)

sucrose (1 trial)

timolol (blocadren) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 4)

HIV Infections (Phase 4)

Immunologic Deficiency Syndromes (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial APIs: 17